{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:21:16Z","timestamp":1772032876034,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T00:00:00Z","timestamp":1366156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00262-013-1415-9","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T11:15:22Z","timestamp":1366110922000},"page":"1041-1052","source":"Crossref","is-referenced-by-count":56,"title":["A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer"],"prefix":"10.1007","volume":"62","author":[{"given":"Daniela","family":"Fenoglio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Traverso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Negrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Kalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florinda","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ferrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Sciallero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Murdaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Setti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Sobrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Boccardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cittadini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Puppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Criscuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Carmignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Indiveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto","family":"Filaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,17]]},"reference":[{"key":"1415_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69\u201390","journal-title":"CA Cancer J Clin"},{"key":"1415_CR2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00262-012-1216-6","volume":"61","author":"N Rigamonti","year":"2012","unstructured":"Rigamonti N, Bellone M (2012) Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother 61:453\u2013468","journal-title":"Cancer Immunol Immunother"},{"key":"1415_CR3","doi-asserted-by":"crossref","unstructured":"Heidenreich A, Pfister D (2012) Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol. doi: 10.1016\/j.eururo.2012.08.048","DOI":"10.1016\/j.eururo.2012.08.048"},{"key":"1415_CR4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.juro.2012.04.108","volume":"18","author":"R Figlin","year":"2012","unstructured":"Figlin R, Sternberg C, Wood CG (2012) Novel agents and approaches for advanced renal cell carcinoma. J Urol 18:707\u2013715","journal-title":"J Urol"},{"key":"1415_CR5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc3223","volume":"12","author":"SS Kwek","year":"2012","unstructured":"Kwek SS, Cha E, Fong L (2012) Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer 12:289\u2013297","journal-title":"Nat Rev Cancer"},{"key":"1415_CR6","first-page":"1387","volume":"34","author":"F Perut","year":"2009","unstructured":"Perut F, Cenni E, Unger RE, Kirkpatrick CJ, Giunti A, Baldini N (2009) Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases. Int J Oncol 34:1387\u20131393","journal-title":"Int J Oncol"},{"issue":"Supplement 8","key":"1415_CR7","doi-asserted-by":"crossref","first-page":"viii22","DOI":"10.1093\/annonc\/mds259","volume":"23","author":"WR Gerritsen","year":"2012","unstructured":"Gerritsen WR (2012) The evolving role of immunotherapy in prostate cancer. Ann Oncol 23(Supplement 8):viii22\u2013viii27. doi: 10.1093\/annonc\/mds259","journal-title":"Ann Oncol"},{"key":"1415_CR8","author":"S Walter","year":"2012","unstructured":"Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med doi. doi: 10.1038\/nm.2883","journal-title":"Nat Med doi"},{"key":"1415_CR9","unstructured":"Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL (2012) Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. (Epub ahead of print) PMID: 22865266"},{"key":"1415_CR10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/350569a0","volume":"350","author":"EH Blackburn","year":"1991","unstructured":"Blackburn EH (1991) Structure and function of telomeres. Nature 350:569\u2013573","journal-title":"Nature"},{"key":"1415_CR11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0959-437X(05)80046-2","volume":"4","author":"CW Greider","year":"1994","unstructured":"Greider CW (1994) Mammalian telomere dynamics: healing, fragmentation shortening and stabilization. Curr Opin Genet Dev 4:203\u2013211","journal-title":"Curr Opin Genet Dev"},{"key":"1415_CR12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1101\/gad.12.8.1073","volume":"12","author":"CI Nugent","year":"1998","unstructured":"Nugent CI, Lundblad V (1998) The telomerase reverse transcriptase: components and regulation. Genes Dev 12:1073\u20131185","journal-title":"Genes Dev"},{"key":"1415_CR13","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3892\/ijo.2012.1611","volume":"41","author":"DE Gomez","year":"2012","unstructured":"Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD, Alonso DF (2012) Telomere structure and telomerase in health and disease (review). Int J Oncol 41:1561\u20131569","journal-title":"Int J Oncol"},{"key":"1415_CR14","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.7605428","volume":"266","author":"NW Kim","year":"1994","unstructured":"Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011\u20132013","journal-title":"Science"},{"key":"1415_CR15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/22780","volume":"400","author":"WC Hahn","year":"1999","unstructured":"Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA (1999) Creation of human tumour cells with defined genetic elements. Nature 400:464\u2013468","journal-title":"Nature"},{"key":"1415_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s004280000189","volume":"437","author":"K Dhaene","year":"2000","unstructured":"Dhaene K, Van Marck E, Parwaresch R (2000) Telomeres, telomerase and cancer: an up-date. Virchows Arch 437:1\u201316","journal-title":"Virchows Arch"},{"key":"1415_CR17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1074-7613(00)80066-7","volume":"10","author":"RH Vonderheide","year":"1999","unstructured":"Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673\u2013679","journal-title":"Immunity"},{"key":"1415_CR18","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1073\/pnas.070560797","volume":"97","author":"B Minev","year":"2000","unstructured":"Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M (2000) Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci 97:4796\u20134801","journal-title":"Proc Natl Acad Sci"},{"key":"1415_CR19","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2005-01-0258","volume":"107","author":"G Filaci","year":"2006","unstructured":"Filaci G, Fravega M, Setti M, Traverso P, Millo E, Fenoglio D, Negrini S, Ferrera F, Romagnoli AR, Basso M, Contini P, Rizzi M, Ghio M, Benatti U, Damonte G, Ravetti JL, Carmignani G, Zanetti M, Indiveri F (2006) Frequency of telomerase-specific CD8\u00a0+\u00a0T lymphocytes in patients with cancer. Blood 107:1505\u20131512","journal-title":"Blood"},{"key":"1415_CR20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1586\/14760584.7.7.881","volume":"7","author":"GL Beatty","year":"2008","unstructured":"Beatty GL, Vonderheide RH (2008) Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 7:881\u2013887","journal-title":"Expert Rev Vaccines"},{"key":"1415_CR21","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-11-1385","volume":"17","author":"PF Brunsvig","year":"2011","unstructured":"Brunsvig PF, Kyte JA, Kersten C, Sundstr\u00f8m S, M\u00f8ller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011) Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I\/II trial. Clin Cancer Res 17:6847\u20136857","journal-title":"Clin Cancer Res"},{"key":"1415_CR22","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00262-011-1061-z","volume":"60","author":"RE Hunger","year":"2011","unstructured":"Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, M\u00f8ller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G (2011) Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother 60:1553\u20131564","journal-title":"Cancer Immunol Immunother"},{"key":"1415_CR23","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/mt.2010.289","volume":"19","author":"SM Rittig","year":"2011","unstructured":"Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+\u00a0and CD4+\u00a0immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19:990\u2013999","journal-title":"Mol Ther"},{"key":"1415_CR24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/CJI.0b013e3181833818","volume":"31","author":"A Berntsen","year":"2008","unstructured":"Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS, Svane IM (2008) Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1\/2 trial. J Immunother 31:771\u2013780","journal-title":"J Immunother"},{"key":"1415_CR25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1479-5876-5-12","volume":"5","author":"X Cortez-Gonzalez","year":"2007","unstructured":"Cortez-Gonzalez X, Zanetti M (2007) Telomerase immunity from bench to bedside: round one. J Transl Med 5:12","journal-title":"J Transl Med"},{"key":"1415_CR26","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00262-006-0145-7","volume":"55","author":"PF Brunsvig","year":"2006","unstructured":"Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, M\u00f8ller M, Eriksen JA, Gaudernack G (2006) Telomerase peptide vaccination: a phase I\/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55:1553\u20131564","journal-title":"Cancer Immunol Immunother"},{"key":"1415_CR27","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1158\/1078-0432.CCR-04-0325","volume":"10","author":"MR Parkhurst","year":"2004","unstructured":"Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA (2004) hTERT: 540\u2013548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10:4688\u20134698","journal-title":"Clin Cancer Res"},{"key":"1415_CR28","first-page":"2127","volume":"63","author":"Z Su","year":"2003","unstructured":"Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63:2127\u20132133","journal-title":"Cancer Res"},{"key":"1415_CR29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/1078-0432.CCR-07-4590","volume":"14","author":"L Wenandy","year":"2008","unstructured":"Wenandy L, S\u00f8rensen RB, Sengel\u00f8v L, Svane IM, thor Straten P, Andersen MH (2008) The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res 14:4\u20137","journal-title":"Clin Cancer Res"},{"key":"1415_CR30","first-page":"2600","volume":"62","author":"R Schroers","year":"2002","unstructured":"Schroers R, Huang XF, Hammer J, Zhang J, Chen SY (2002) Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+\u00a0T-Helper cells. Cancer Res 62:2600\u20132605","journal-title":"Cancer Res"},{"key":"1415_CR31","first-page":"4743","volume":"9","author":"R Schroers","year":"2003","unstructured":"Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen SY (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743\u20134755","journal-title":"Clin Cancer Res"},{"key":"1415_CR32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1415_CR33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/CVI.00316-07","volume":"15","author":"P Durando","year":"2008","unstructured":"Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, Renzoni A, Fabbri P, Ferrera A, Parodi A, Bruzzone B, Gabutti G, Podda A, Del Giudice G, Fragapane E, Indiveri F, Crovari P, Gasparini R (2008) Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 15:253\u2013259","journal-title":"Clin Vaccine Immunol"},{"key":"1415_CR34","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1073\/pnas.0703395104","volume":"104","author":"D Valmori","year":"2007","unstructured":"Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O\u2019Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody\/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104:8947\u20138952","journal-title":"Proc Natl Acad Sci USA"},{"key":"1415_CR35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cyto.a.20189","volume":"68","author":"K Godoy-Ramirez","year":"2005","unstructured":"Godoy-Ramirez K, M\u00e4kitalo B, Thorstensson R, Sandstr\u00f6m E, Biberfeld G, Gaines H (2005) A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A 68:71\u201380","journal-title":"Cytometry A"},{"key":"1415_CR36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1399-0039.1998.tb03057.x","volume":"52","author":"NT Young","year":"1998","unstructured":"Young NT, Mulder A, Cerundolo V, Claas FH, Welsh KI (1998) Expression of HLA class I antigens in transporter associated with antigen processing (TAP)-deficient mutant cell lines. Tissue Antigens 52:368\u2013373","journal-title":"Tissue Antigens"},{"key":"1415_CR37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0022-1759(88)90079-8","volume":"110","author":"C Czerkinsky","year":"1988","unstructured":"Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O (1988) Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 110:29\u201336","journal-title":"J Immunol Methods"},{"key":"1415_CR38","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.4049\/jimmunol.175.9.5765","volume":"175","author":"E Amyes","year":"2005","unstructured":"Amyes E, McMichael AJ, Callan MF (2005) Human CD4+\u00a0T cells are predominantly distributed among six phenotypically and functionally distinct subsets. J Immunol 175:5765\u20135773","journal-title":"J Immunol"},{"key":"1415_CR39","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.4049\/jimmunol.178.7.4112","volume":"178","author":"P Romero","year":"2007","unstructured":"Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, Corthesy P, Devevre E, Speiser DE, Rufer N (2007) Four functionally distinct populations of human effector-memory CD8\u00a0+\u00a0T lymphocytes. J Immunol 178:4112\u20134119","journal-title":"J Immunol"},{"key":"1415_CR40","first-page":"1235","volume":"6","author":"WK Oh","year":"2006","unstructured":"Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW (2006) Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 6:1235\u20131240","journal-title":"Urology"},{"key":"1415_CR41","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/cncr.21695","volume":"106","author":"J Michels","year":"2006","unstructured":"Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K (2006) First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 106:1041\u20131046","journal-title":"Cancer"},{"key":"1415_CR42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.semcancer.2003.09.001","volume":"13","author":"G Parmiani","year":"2003","unstructured":"Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M (2003) Immunotherapy of melanoma. Semin Cancer Biol 13:391\u2013400","journal-title":"Semin Cancer Biol"},{"key":"1415_CR43","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0952-7915(98)80228-8","volume":"10","author":"DM Pardoll","year":"1998","unstructured":"Pardoll DM, Topalian SL (1998) The role of CD4+\u00a0T cell responses in antitumor immunity. Curr Opin Immunol 10:588\u2013594","journal-title":"Curr Opin Immunol"},{"key":"1415_CR44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0198-8859(92)90068-X","volume":"33","author":"MA Fernandez-Vi\u00f1a","year":"1992","unstructured":"Fernandez-Vi\u00f1a MA, Falco M, Sun Y, Stastny P (1992) DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. Hum Immunol 33:163\u2013173","journal-title":"Hum Immunol"},{"key":"1415_CR45","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/1521-4141(200109)31:9<2642::AID-IMMU2642>3.0.CO;2-6","volume":"31","author":"M Ayyoub","year":"2001","unstructured":"Ayyoub M, Migliaccio M, Guillaume P, Li\u00e9nard D, Cerottini JC, Romero P, L\u00e9vy F, Speiser DE, Valmori D (2001) Lack of tumor recognition by hTERT peptide 540\u2013548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 31:2642\u20132651","journal-title":"Eur J Immunol"},{"key":"1415_CR46","first-page":"3184","volume":"62","author":"A Lev","year":"2002","unstructured":"Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, Hoogenboom HR, Reiter Y (2002) Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 62:3184\u20133194","journal-title":"Cancer Res"},{"key":"1415_CR47","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1078-0432.CCR-0620-3","volume":"10","author":"RH Vonderheide","year":"2004","unstructured":"Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM (2004) Vaccination of cancer patients against telomerase induces functional antitumor CD8+\u00a0T lymphocytes. Clin Cancer Res 10:828\u2013839","journal-title":"Clin Cancer Res"},{"key":"1415_CR48","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1158\/0008-5472.CAN-04-2991","volume":"65","author":"J Dupont","year":"2005","unstructured":"Dupont J, Latouche JB, Ma C, Sadelain M (2005) Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 65:5417\u20135427","journal-title":"Cancer Res"},{"issue":"Suppl 3","key":"1415_CR49","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1016\/j.vaccine.2010.07.022","volume":"28","author":"M Moser","year":"2010","unstructured":"Moser M, Leo O (2010) Key concepts in immunology. Vaccine 28(Suppl 3):C2\u2013C13","journal-title":"Vaccine"},{"key":"1415_CR50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","volume":"1","author":"J Aucouturier","year":"2002","unstructured":"Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V (2002) Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 1:111\u2013118","journal-title":"Expert Rev Vaccines"},{"key":"1415_CR51","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.vaccine.2005.10.045","volume":"24","author":"D Johnston","year":"2006","unstructured":"Johnston D, Bystryn JC (2006) Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 24:1958\u20131965","journal-title":"Vaccine"},{"key":"1415_CR52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/PPO.0b013e3182346320","volume":"17","author":"SE Church","year":"2011","unstructured":"Church SE, Jensen SM, Twitty CG, Bahjat K, Hu HM, Urba WJ, Fox BA (2011) Multiple vaccinations: friend or foe. Cancer J 17:379\u2013396","journal-title":"Cancer J"},{"key":"1415_CR53","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-013-1415-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-013-1415-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-013-1415-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T12:40:34Z","timestamp":1562935234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-013-1415-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,17]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["1415"],"URL":"https:\/\/doi.org\/10.1007\/s00262-013-1415-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,17]]}}}